Pharmaceutical Quality Intelligence. Inspection-Ready Judgment.
Will your procedures, investigations, and quality decisions hold up under regulatory scrutiny? DSRV helps pharma teams find inspection exposure before an inspector does.
How DSRV Works
Every page, article, and service maps to one of three pillars — intelligence, response, or triage.
Intelligence
Know what's happening before it happens to you.
Quality leaders, consultants, and pharma firms tracking regulatory risk.
- FDA warning letters & 483 trend analysis
- Enforcement pattern identification
- ICH, EMA, and USP regulatory updates
- Weekly enforcement intelligence digests
Response Strategy
Structured responses to regulatory and quality challenges.
Companies facing active FDA, audit, or quality issues who need a structured path forward.
- FDA 483 response frameworks
- Remediation planning & CAPA guidance
- Stability gap assessments
- Data integrity remediation support
Inspection Risk Scan
See what an inspector would find in your documents.
QA managers, quality directors, and consultants who need to pressure-test documents before inspection.
- Submit SOPs, deviations, CAPAs, or investigations
- Scored across six enforcement-informed risk dimensions
- Specific findings tied to real FDA enforcement patterns
- Recommended fixes with regulatory context
About DSRV
Stability-first intelligence for pharma teams
Founder credibility, practical judgment, and a workflow built for real decisions.
DSRV helps pharmaceutical teams handle stability, submission readiness, and high-stakes quality work with clarity.
Proof points
- Hands-on stability and submission experience across multiple dosage forms
- Built for teams that need the work routed to the right lane fast
- Editable by Admin so the site can stay current without a deploy
Pharmaceutical intelligence, traceable to the source.
Built for teams that need faster answers without losing traceability.
The Vault is a searchable pharmaceutical knowledge system built from real source documents. Ask a question in plain English and get a source-backed answer with citations you can trace back to the original material.
Try asking
“What's the half-life of rivaroxaban in patients with renal impairment?”
{
"question": "What's the half-life of rivaroxaban
in patients with renal impairment?"
}{
"answer": "Rivaroxaban's terminal half-life is
~5-9h in healthy adults, extending to
9-13h in moderate renal impairment...",
"sources": [
{ "title": "Xarelto Prescribing Information §12.3" },
{ "title": "Kubitza et al., Br J Clin Pharmacol 2010" }
]
}Curated topic coverage · pilot preview
Grounded in real documents
Every answer is built from source documents inside the library. When coverage is limited, the response says so rather than improvising.
Traceable by design
Every claim links back to the document it came from. Review the source, verify the context, and move on with confidence.
Access by request
Try the public preview today. API access is granted case-by-case to pilot users building internal pharmaceutical tools.
From DSRV
Subscribe free to unlock full articles and weekly round-ups.
April 2026
Chemco Warning Letter Cleaning Component Controls
title: "FDA Tied Residue, Cleaning, and Component Failures at Chemco"
DSRV Intelligence
·6 min read
2026-04-02
Contract Testing Labs Keep Exposing GMP Control Gaps
Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk.
DSRV Intelligence
·5 min read
2026-04-04
What FDA's Data Integrity Remediation Demands Actually Reveal
When FDA's warning letters require independent assessments, patient-risk analyses, and global CAPA strategies, the agency is not just describing consequences. It is disclosing the standards it expected to find before the inspection started.
DSRV Intelligence
·5 min read
2026-04-04
Multi-Product API Facilities and the Contamination Gap FDA Finds
FDA's March 2026 warning letter to Henan Lvyuan Pharmaceutical points to a contamination control failure pattern that is structurally embedded in how most multi-product API facilities operate. The gap is not usually in the SOP. It is in the evidence.
DSRV Intelligence
·5 min readFull articles unlock with a free subscription.
No spam. Unsubscribe any time. Weekly regulatory round-up included.
Not a law firm. Not a CRO. Not SaaS boilerplate.
A pharma quality risk engine — purpose-built to evaluate whether your documents, investigations, and decisions are defensible under regulatory scrutiny.
50%+ of FDA warning letters in 2025 cited inadequate responses to prior 483 observations.
The response itself — not the original finding — triggers enforcement escalation.
Enforcement-Informed Speed
Risk diagnostics in minutes, response strategy memos in days. Scored against real FDA enforcement patterns, not generic checklists.
Accessible Pricing
Enterprise-level quality support without the enterprise contract. Start free, pay only when you need structured response work.
Deep Pharma Focus
Purpose-built for small pharma quality gaps — not a horizontal QMS bolted onto pharma. Deep domain expertise compounds with every engagement.
Real-World Expertise
Built by a working quality professional who reads the same warning letters and guidance documents you do. No hallucinated claims, no boilerplate.
The numbers behind the problem
Small pharma quality teams face the same regulatory scrutiny as large enterprises — with a fraction of the resources. DSRV exists to close that gap.
50%+
FDA warning letters in 2025 cited inadequate responses to prior 483 observations
$150K+
Average cost of traditional consulting engagement for a single 483 response strategy
15 days
Typical FDA response window — most small pharma teams don't have a playbook ready
Built on real regulatory data
- FDA warning letter database analysis
- 483 observation pattern tracking
- ICH, EMA, and USP guidance monitoring
- Real enforcement action trend data
Who's behind DSRV
Founded by a working pharmaceutical quality professional with hands-on experience in GMP manufacturing, regulatory submissions, and quality system design.
Every analysis, framework, and recommendation is grounded in the same regulatory realities you navigate daily — not theoretical compliance advice.
The regulatory world doesn't slow down.
Neither should you.
Join QA professionals, regulatory affairs specialists, and stability scientists who rely on DSRV for weekly regulatory updates, quality science deep-dives, and expert commentary.
Free forever. No spam. Unsubscribe any time.
Will your documents hold up under inspection?
Submit your SOP, deviation report, CAPA, or investigation. Get a scored risk diagnostic across six enforcement-informed dimensions — with specific findings, inspection-risk signals, and recommended fixes.